Wah Academia Journal of Health and Nutrition

Homepage: https://wajhn.com/index.php/journal

Original Article

Open Access

mRNA-Based Viral Vaccines: Revolutionizing Prophylaxis through Biotechnological Innovations and Virological Insights

Ali Abbas[a*], Faiqa Shakeel[b], Romisa Sattar[c], Amna Noor[d], Sidra Riaz[e], Kanwal Saeed[f], Muhammad Salman[g] and Muhammad Sanish Arif[h]

[a] Department of Microbiology, Government College University, Faisalabad, Pakistan
[b] Faculty of Engineering and science (FES), University of Greenwich, United Kingdom
[c] Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, Pakistan
[d] Coordinator PhD. Microbiology and Molecular Biology, Department of Pathology, Rawalpindi Medical University, Pakistan
[e] Scientific Adviser, Ministry of Science and Technology, Islamabad, Pakistan
[f] School of Biological Sciences, Punjab University, Lahore, Pakistan
[g] Department of biological sciences, faculty of sciences, Superior University, Lahore, Pakistan
[h] Department of pathobiology, University of Veterinary and Animal Sciences, Jhang Campus, Pakistan

Article Information

Received 5 May 2025

Accepted 25 June 2025

Available online 30 June 2025

Keywords: mRNA vaccines, viral immunoprophylaxis, lipid nanoparticles

Abstract

The post-genomic and post-pandemic era has brought about a paradigm shift in the realm of vaccinology, which has triggered a transition from empirical whole-pathogen strategies to rational information-driven molecular design. The sudden and spectacular rise of messenger RNA (mRNA) vaccines is a disruptive prophylactic technology, whose efficacy has been unequivocally proven on a global platform during the COVID-19 pandemic. The unprecedented success of mRNA vaccines is a direct result of the strategic convergence of synthetic biology, structural virology, and immunoengineering. As a form of programmable biological software, mRNA vaccines provide a precise set of genetic instructions for the in vivo production of antigens, thereby inducing a coordinated humoral and cellular immune response. The review article will cover the multi-disciplinary underpinnings of the technology, its translation from bench to global platform, and the future frontiers that will be enabled by the strategic integration of artificial intelligence and synthetic biology, which will firmly establish mRNA vaccinology as a cornerstone of 21st-century medicine.

Introduction

The course of history of viral vaccines has been from live-attenuated and inactivated whole virus preparations to recombinant subunit and viral vector approaches [1], [2]. Although these conventional approaches have been monumental successes in controlling endemic diseases, they may inherently have limitations in dealing with rapidly emerging and antigenically diverse viruses. The development periods may be long, and the approaches may not be effective in inducing potent cytotoxic T-cell immune responses necessary for the clearance of intracellular viruses [3], [4].

Nucleic acid-based vaccines, which were first envisioned decades ago, have now come to fill this void. Of these, mRNA vaccines have had a spectacular success story in clinical trials [5]. In essence, these vaccines mark a transition from the delivery of the antigen itself to the delivery of the information for its production. The synthetic mRNA carrying the gene for a viral antigen is encapsulated and administered to host cells, which are then hijacked to use the host's own translational apparatus to produce the antigen in situ [6]. This process of endogenous production recreates the essential features of a natural viral infection, including the endogenous processing and presentation of the antigen on both MHC Class I and II molecules, thus inducing a balanced immune response [7]. This review aims to illuminate the interdisciplinary convergence that has made this success possible, including the Virological intelligence that guides rational antigen design, the biotech advances that have made mRNA stable and targeted, and the immunological fundamentals that define efficacy and memory.

https://doi.org/10.63954/67v24t98

We also examine the translational imperatives that currently define this technology and speculate on future directions for this programmable technology in the medical toolbox.

Virological Intelligence Driving mRNA Vaccine Design

Building a successful mRNA vaccine is a process that predates any recent chemistry, as it involves a profound understanding of the virus itself. Virology provides the necessary blueprint.



Figure 1.0 Development procedure of mRNA vaccine

❖ **Viral Genomics as the Blueprint for Antigen Engineering**

But as sequencing is now becoming fast, inexpensive, and scalable, it is possible to paint the complete antigenic map for a novel virus threat in mere days. And the SARS-CoV-2 experience taught us this lesson all too well: the genome sequence was made public worldwide in January 2020, and soon virtual designs for vaccine antigens against the spike protein could be produced [8], [9]. Then came structural virology and cryo-electron microscopy to provide us with atomic-level blueprints. These reveal the native, pre-fusion conformation of the surface proteins and help to guide antigen design to display the key neutralizing epitopes while excluding or suppressing the immunodominant, non-neutralizing, or even infection-triggering parts [10].

❖ **Conserved vs. Variable Viral Targets**

The Breadth vs. Precision Paradox "The fitness costs imposed on a virus that replicates in a human host for a lifetime rather than a short period are significant," explains John Fleming. "The virus has to have a minimal impact on its host to survive. We need to target not just the virus itself but also its need to survive in its host." [11].

"The biggest problem in antiviral vaccine design is that viruses change rapidly. We aim to target regions that are conserved and functionally constrained to control immune escape. In coronaviruses like SARS-CoV-2, the receptor-binding domain or, more successfully now, the prefusion-stabilized full-length S protein is now targeted predominantly, although its high mutation rate in newer strains is a concern [12]. In influenza viruses, targeting the conserved stalk domain of hemagglutinin and neuraminidase is poised to transition towards achieving 'universal' vaccine coverage targeting strain-specific head regions [13]. In HIV and HCV infections, high envelope protein sequence variability has led to exploring sites for targeting 'cryptic' or 'conserved' epitopes or 'mosaic' sequences to increase broadness. In flavivirus infections like dengue or Zika virus infections, 'engineering of antigens that stabilize E protein 'dimers' in a prefusion conformation to induce [14], [15].

❖ **Antigen Conformation and Viral Entry Mechanisms**

The shape of an antigen is inevitably linked with function and immune system perception [16]. The switch to prefusion-stabilized SARS-CoV-2 spike with the S-2P mutations was a turning point, as it locks the spike into an open conformation, preventing reversion to the final, post-fusion shape and maintaining it in a metastable state recognizable to potent neutralizing antibodies [17]. Similarly, understanding the pH-dependent fusion strategy of the influenza virus HA or the mechanisms by which conserved HIV Env epitopes remain hidden could inform the design of vaccine targets based on the shape of the molecules [18].

The objective is to display the viral 'Achilles' heel', or the machinery of entry, in the most susceptible, antibody-like accessible shape.



Figure 2.0. Viral Targets and the regions on which vaccines act

mRNA Engineering: From Instability to Clinical Robustness

The journey of mRNA from a notoriously unstable compound to a useful therapeutic agent is one of thoughtful molecular design.

❖ Nucleoside Modifications and Trans

One critical milestone was achieved with the incorporation of naturally occurring modified nucleosides such as pseudouridine (Ψ) and its derivative N1-methylpseudouridine (m1Ψ), initiated by Katalin Karikó and Drew Weissman [19]. This shifted the mRNA from being recognized as a foreign entity by the immune system. Modified nucleosides are critical in suppressing the recognition of central innate sensors, Toll-like receptor 7 (TLR7) and Protein Kinase R (PKR), which cause reduced translation due to triggering of Type I interferon. This concept of "immune evasion" is crucial as it increases both the translation efficiency of mRNA and its stability. Codon optimization techniques are not only focused on increasing translation speed but also work towards optimizing protein folding through correctly optimized translation rates that avoid ribosomal stalling as well as incorrect nucleoside incorporation, which reduces CPD G content and triggers Toll-Like Receptor 9 [20], [21].



Figure 3.0 illustrates key mRNA engineering strategies for evading immune detection, enhancing stability, and optimizing translation

❖ Structural Elements of Synthetic mRNA: A Finely Tuned Cassette

A synthetic mRNA vaccine construct comprises a carefully designed cassette of essential regulatory elements: [22]. 5′ Cap: Cap analogs such as Clean Cap for co-transcriptional capping are necessary for efficient capping of the mRNA transcript. Capping is a critical process for translation initiation, mRNA stability, and general recognition of 'self' versus 'non-self' mRNA. Untranslated Regions (UTR): The 5′ and 3′ UTRs are engineered often using coding sequences like α- or β-globin genes with high transcript levels in humans to regulate the half-life and localization functions and the feasibility of translation [23]. Poly(A) Tail: This defined tail of 100-150 nucleotides protects from exonuclease digestion and in addition to the cap, enhances translation. It is a measurement of quality to be of specific length [24]. Alternative Platforms: There is self-amplifying RNA (saRNA) with the alphavirus genome. It has both the replicase and the antigen [25]. This allows it to be amplified at the cellular level and express a high level of antigen. Circular RNAs are extremely stable because they do not have free ends [26].

❖ Quality Control in mRNA Production

It is In vitro transcription can produce byproducts that stimulate the immune system and include double-stranded RNA, particularly in RNA transcripts produced by in vitro transcription [27]. These molecules are potent activators of pattern-recognition receptors such as RIG-I and MDA5 and the protein kinase PKR and strongly induce interferon. Hence, purification techniques such as HPLC and cellulose filtration are required. Purified RNA is characterized by consistency, high purity, predictable pharmacokinetics, and a favorable safety profile [28].

Lipid Nanoparticles as Artificial Viral Mimics

Without a delivery mechanism, unprotected mRNA would degrade quickly and not be absorbed efficiently. It was the discovery of LNPs that provided the crucial carrier to make mRNA a realistic treatment.

The contemporary LNP typically comprises four components: ionizable cationic lipid (playing the central role in the release of the particle from the endosome), phospholipid (helping lipid), cholesterol (for the stability and fluidity of the membrane), and PEGylated lipid (regulating the particle size and preventing opsonization) [29]. Once taken up through the endocytosis process by the cell, the ionizable lipid, being positively charged in the endosomal environment, triggers the destabilization of the endosomal membrane, ensuring the release of the mRNA into the cellular cytoplasm. This release process represents the primary pathogen for low efficacy [30]. It has been found through biodistribution analysis that the intramuscular injection of the LNP-mRNA complex primarily accumulates at the injection site and draining lymph nodes and, importantly, a considerable amount at the liver site. This targeting of the liver can be attributed to the apolipoprotein E binding and can significantly affect the choice of antigen and evaluation of hepatotoxicity [31].

The moment LNPs come into contact with bodily fluid, they get masked by the constantly changing layer of adsorbed proteins and form a “protein corona.” The protein corona itself becomes the biological identity of the particles, which determines the fate and the type of immune reaction the particles trigger [32]. It may, therefore, affect the rate or occurrence of reactions such as fever, chills, and muscle aches, which occur with the mRNA-LNP vaccine, a fraction of which is contributed by the innate immune cells, monocytes and neutrophils, which the RNPs trigger as an intrinsic adjuvant [33].

https://doi.org/10.63954/67v24t98



Figure 4.0 illustrates the structure of a lipid nanoparticle (LNP) and its stepwise endocytic delivery process to release mRNA into the cytoplasm for protein synthesis.

Biodegradable Lipids: New ionizable lipids that have ester bonds, which allow them to biodegrade easily in the body.

Innate Immune Sensing: Friend or Foe?

The relationship between the mRNA-LNP vaccine and the innate immune system is a matter of finding a balance: you want it to be active enough to induce a robust response, but not too active to cause harm.

- **Pattern Recognition Receptors and mRNA Vaccines**

Our own immune protection is dependent on a repertoire of pattern recognition receptors, or PRRs. mRNA vaccines activate multiple such receptors: TLR3 (double-stranded-RNA) from endosomes, TLR7/8 (single-stranded RNA), or cytoplasmic sensors like RIG-I/MDA5 (dsRNA or specific RNAs) [34]. Upon stimulation, the pathways activate NF-κB/IRF signaling pathways to produce type-I interferons, pro-inflammatory mediators like IL-6/TNF-α. As such, reactogenicity (pain/fever) triggers via local/general inflammation is achieved. Most importantly, however, “danger signals” are generated for dendritic cell priming and T-cell activation for full immune response activation [35].

- **Balancing Innate Activation and Antigen Expression**

The challenge lies in finding a balance here. Too much of the interferon response can lead to a suppression of the translation of the encoded antigen and hence reduced immunogenicity [36]. Methods such as nucleoside modification and purification are largely intended for a modulation of these responses and a shift from a strong antiviral response to a stimulatory one. The lipid nanoparticle part itself can be considered a kind of adjuvant. The idea here is that there should be a balance maintained between a stimulatory innate response and a reduced toxic effect and reduced production of antigen [37].

- **How Systems Immunology**

Also, advanced analyses of high-dimensional data, such as transcriptomics, proteomics, and metabolomics, of the early phase following vaccinations are currently revealing immunological profiles associated with the magnitude and quality of subsequent adaptive immunity [38]. Thus, early peaks of specific cytokines and interferon-stimulated genes are associated with high levels of antibody responding to vaccinations. Such profiles could serve as predictive markers of vaccinations in individuals or populations [39].

Adaptive Immune Programming by mRNA Vaccines

Finally, the success of any vaccine resides in its capability to invoke robust and persistent protective immune responses. The mRNA-LNP-based vaccines are highly successful in this respect.

- **B Cell Responses and Germinal Center**

Dynamics "mRNA-LNP vaccines elicited highly vigorous and protracted germinal center responses in draining lymph nodes." These germinal centers are the sites for the improvement of the receptor affinity of the B cells by somatic hypermutation and selection for affinity maturation [40]. In SARS-CoV-2 studies, the germinal center response remained protracted for months, which led to the development of memory B cells with high affinity and class-switched commitment, as well as long-lived plasma cells that migrate into the bone marrow for sustained antibody production. The quality, which refers to affinity, potency, and breadth of reactivity, depends on the "final antigen shape delivered [41].

- **$CD4^+$ and $CD8^+$ T Cell Polarization**

One of the most advantageous aspects of the mRNA LNPs approach is its remarkable ability to induce CD4+ T helper cells and, more importantly, CD8+ cytotoxic T lymphocytes (CTLs) [42]. Because the antigen is being expressed directly in the cytoplasm of the host cells, it follows naturally that this will be taken up by the MHC I antenna, thereby priming the CD8+ T lymphocytes. Immunogens formulated on this platform will preferentially invoke a Th1 response in CD4+ lymphocytes, which responds with IFN-gamma and IL-2, an effective response for combatting viral pathogens. This CTL response will be vital for eliminating infected host cells, conferring protection supernumerary to antibody-mediated responses, to shield against disease and even cross-protection for variants refractory to humoral responses [43].

- **Immune Memory and Durability**

Memory B/T cells elicited by mRNA vaccines can persist for many months or even years [44]. However, sterilizing immunity at mucosal surfaces, such as the NP surface, can wane with reduced antibody titers, particularly secretory IgA. This is why vaccine efficacy against infection or transmission usually wanes with time, although it remains protective against severe infection due to the long-lasting memory B/T cells and bone marrow plasma cells [45].

mRNA Vaccines in Light of Viral Evolution

Viruses evolve. Either the vaccine has to adapt or stay a step ahead. It is its adaptability that makes the mRNA platform so clever.

❖ **Antigenic Drift, Shift, and Vaccine**

As the mRNA vaccines are modular, the main task in the upgrade is simply the exchange of the genetic sequence in the DNA template [46]. This enabled the "rapid design and development of the vaccines" and occurred quickly for Omicron boosters. However, it can also be noted that the major drawback of such "pandemic chasing" involves the "surveillance, detection, preparation, and revaccination," which may not always be quicker for viruses that "multiply at the speed of lightning [47]."

❖ **Variant-Proof and Pan-Viral Vaccine**

Scientists are now seeking proactive methods [48]:

Conserved Epitope Focus: Designing antigens that draw attention to mutationally constrained and functionally crucial areas (such as RBD stem and HA stalk).

Mosaic Antigens: Leveraging computation to build one protein sequence by combining different strains or variants by trying to lure with common characters. This is a prominent concept for universal influenza and HIV vaccines [49].

Multivalent Constructs: Using one mRNA that encodes multiple different antigens or multiple mRNAs to offer broader protection.

❖ **RNA Virus Surveillance by mRNA Analyses**

mRNA virus surveillance It can also strictly be integrated with global genomic surveillance systems. Once the concerning sequences are recognized, they will instantly be input into the vaccine designing software as well as produced on a massive scale in a few weeks [50]. This will help provide a strong "test to deploy"/"prototype to respond" strategy for pandemic preparedness with a library of prototype vaccines to enter clinical trials against the pandemic pathogen candidates [51].

Clinical Translation: Lessons from COVID-19 and Beyond

The COVID-19 pandemic suddenly became a huge reality show lab that stacked up a huge volume of clinical data.

❖ **Efficacy, Safety, and Real**

Phase III studies for BNT162b2 and mRNA-1273 demonstrated a 95% efficacy rate in protecting from symptomatic COVID-19 [52], [53]. Real-world efficacy studies with millions of participants indicated a robust defense mechanism against hospitalization, death, and severe cases of COVID-19 due to even Delta variants. The efficacy in preventing infection and transmission was high initially but reduced over time due to immune-evaded variants such as Omicron [54]. The primary safety concern has been myocarditis and pericarditis. These conditions are a rare occurrence and are self-limiting; however, it has been found that the benefits clearly outweigh the side effects [55].

❖ **Special Populations**

Immunocompromised Persons: Patients with solid organ transplants, B-cell-depleting agents, or severe HIV infection may have reduced immunity, necessitating increased amounts, additional booster shots, or pre-exposure prophylactic antibodies [56].

Pediatric & Geriatric Groups: Responses at both age extremes are high; however, levels of reactogenicity are variable. Seniors achieve a slight decrease in maximal antibody levels; nevertheless, they achieve a significant benefit in protection against severe disease. In children, high responses are induced; some may have a higher relative neutralizing antibody titer [57].

❖ **Comparative Effectiveness vs. Other Platforms**

Direct head-to-head comparisons are difficult. Generally, mRNA vaccines are expected to induce higher levels of neutralizing antibodies compared with adenovirus or protein subunit vaccines. Immune responses to the generated antigens are robust, but details of these vary. Durability, cross-reactivity with variants, or interactions of various boosters are some areas that are currently being actively researched, with various studies indicating that more robust immunity can be achieved with a booster [58].

Manufacturing, Equity, and Global Deployment Challenges While scientific success is necessary, it must also be complemented by logistics and ethics to bring benefits to the world.

❖ **Cold Chain and Stability Innovations**

The earlier versions of the mRNA-based COVID-19 vaccines also called for ultra-cold chain storage at temperatures of -20°C to -80°C [59]. The current research and development are showing positive outcomes, with the development of the next-generation lipid nanoparticles having improved thermostability and lyophilization techniques for freeze-drying that can facilitate storage of the mRNA-based vaccines at 2-8°C or even room temperature [60].

❖ **Decentralized & Modular Manufacturing**

One strong aspect is the completely synthetic process using cell-free technology. It is easily scalable and amenable to modular regional facilities with standardized equipment and protocols. It is easily scalable and amenable to modular regional facilities with standardized equipment and protocols. It is easily scalable and amenable to modular regional facilities with standardized equipment and protocols. It is easily scalable and amenable to modular regional facilities with standardized equipment and protocols [61].

❖ **Ethical and geopolitical considerations**

The pandemic has exposed the fault lines in access to vaccines and was further aggravated by the onset of vaccine nationalism,

https://doi.org/10.63954/67v24t98

export curbs, and IP disputes [62]. Although mRNA technology has the genuine promise of equitable access because of its manufacture ability, it is necessary to ensure that the promise is fulfilled. Initiatives such as the mRNA technology transfer hub announced at the WHO headquarters in South Africa are the key to making the revolution inclusive [63].

Beyond Prevention: Expanding the Functional Scope of mRNA Vaccines

The platform also goes beyond viral disease prevention by vaccine products. There are already trials for its potential use in treating disease: clinical trials are being carried out for mRNA-therapeutic vaccines targeting chronic infections such as HIV, HBV, and Herpesviruses, as well as cancer, including personalized Neoantigen vaccines targeted to individual tumors [64]. The rapid replication capability also means personalization envisages individual cancer vaccines ready to target specific tumor mutations discovered weeks ago, for instance. In pandemic outbreaks, there can also be "on-demand" vaccines formulated against a zoonotic disease newly discovered in a pandemic spot area [65].

Moreover, there may be the ability to prevent spillover events using the concept of One Health. This may include the vaccination of animal reservoirs or "intermediate hosts" against viruses with a high spillover probability using LNP species-specific formulations to halt pandemics in their tracks [66].

Future Horizons: Artificial Intelligence, Synthetic Biology, and Predictive Vaccinology

The future age is all about integrated digital technology. Just imagine:

AI-assisted antigen discovery: Machine learning algorithms have the potential to predict protein structures, model antigen and antibody binding interactions, rank the immunodominance hierarchy, and design optimal antigen sequences [67].

Digital twins of the immune system: Thus, by integrating multi-omics profiles in people, "digital twins" of the immune system could predict how different vaccine candidates would work and could be used to virtually screen and tailor vaccines to individuals [68].

Self-containing vaccine ecosystems: with the aid of AI, the capacity to generate vaccine candidates through robotics and micro-factories could potentially be used to develop closed systems that switch from preparation for general infection protection to the production of candidate vaccines in the face of a pandemic threat within a short period, in terms of days [67].

Conclusions and Perspectives

mRNA vaccines have transformed the paradigm that exists for shielding individuals against the threat of viruses. They represent the dawn of a new era in vaccinology that appears to be becoming an exact science. It has been less than two years since this brilliant idea has evolved to become a lifesaving device that reached all corners of the planet. It is astounding to think that this is all the result of virology and immunology working together in perfect harmony.

Nevertheless, a set of big questions persists. We should define exactly distribution pathways of lipid nanoparticle carriers within a body and their fate in order to discover what constitutes a basis for a strong mucosal immunity and identify a marker of protection rather than a neutralizing antibody for complex viruses. The dream about a universal vaccine resistant to variants and covering a wide set of viral families continues.

Going forward, science must demand both improved and stronger platforms but also a commitment to ethics and equity in access to technology. Integration with discovery using AI and global surveillance will lead to developing and enhancing a strong preparedness platform against pandemics in the world. It is a critical moment in veterinary and human medicine when "mRNA vaccinology is not just a new technology it is a platform technology with great potential to protect future generations against future pandemics and to provide life-saving therapies against chronic diseases.

Conflict of Interest: NIL

Funding Sources: NIL

References

[1] S. Plotkin, "History of vaccination," Proc. Natl. Acad. Sci., vol. 111, no. 34, pp. 12283–12287, Aug. 2014, doi: 10.1073/pnas.1400472111.

[2] B. S. Graham, J. R. Mascola, and A. S. Fauci, "Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases," JAMA, vol. 319, no. 14, p. 1431, Apr. 2018, doi: 10.1001/jama.2018.0345.

[3] A. J. Pollard and E. M. Bijker, "A guide to vaccinology: from basic principles to new developments," Nat. Rev. Immunol., vol. 21, no. 2, pp. 83–100, Feb. 2021, doi: 10.1038/s41577-020-00479-7.

[4] A. Farrell, "Stemming colitis," Nat. Med., vol. 19, no. 1, pp. 29–29, Jan. 2013, doi: 10.1038/nm.3067.

[5] A. M. Reichmuth, M. A. Oberli, A. Jaklenec, R. Langer, and D. Blankschtein, "mRNA Vaccine Delivery Using Lipid Nanoparticles," Ther. Deliv., vol. 7, no. 5, pp. 319–334, May 2016, doi: 10.4155/tde-2016-0006.

[6] N. Pardi, M. J. Hogan, and D. Weissman, "Recent advances in mRNA vaccine technology," Curr. Opin. Immunol., vol. 65, pp. 14–20, Aug. 2020, doi: 10.1016/j.coi.2020.01.008.

[7] N. Vabret et al., "Immunology of COVID-19: Current State of the Science," Immunity, vol. 52, no. 6, pp. 910–941, Jun. 2020, doi: 10.1016/j.immuni.2020.05.002.

[8] N. D. Grubaugh et al., "Tracking virus outbreaks in the twenty-first century," Nat. Microbiol., vol. 4, no. 1, pp. 10–19, Dec. 2018, doi: 10.1038/s41564-018-0296-2.

[9] F. Wu et al., "A new coronavirus associated with human respiratory disease in China," Nature, vol. 579, no. 7798, pp. 265–269, Mar. 2020, doi: 10.1038/s41586-020-2008-3.

[10] P. A. Weidenbacher and P. S. Kim, "Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope," Proc. Natl. Acad. Sci., vol. 116, no. 20, pp. 9947–9952, May 2019, doi: 10.1073/pnas.1822062116.

[11] R. Cornelis and Z. Shulman, "Upper airway and brain protection by plasma cells: A local affair," Immunity, vol. 55, no. 11, pp. 1972–1974, Nov. 2022, doi: 10.1016/j.immuni.2022.10.012.

[12] D. Wrapp et al., "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation," Science, vol. 367, no. 6483, pp. 1260–1263, Mar. 2020, doi: 10.1126/science. abb2507.

[13] J. R. Bailey, E. Barnes, and A. L. Cox, "Approaches, Progress, and Challenges to Hepatitis C Vaccine Development," Gastroenterology, vol. 156, no. 2, pp. 418–430, Jan. 2019, doi: 10.1053/j.gastro.2018.08.060.

[14] M. C. Crank et al., "A proof of concept for structure-based vaccine design targeting RSV in humans," Science, vol. 365, no. 6452, pp. 505–509, Aug. 2019, doi: 10.1126/science. aav9033.

[15] J. L. Slon Campos, J. Mongkolsapaya, and G. R. Screaton, "The immune response against flaviviruses," Nat. Immunol., vol. 19, no. 11, pp. 1189–1198, Nov. 2018, doi: 10.1038/s41590-018-0210-3.

[16] A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Veesler, "Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein," Cell, vol. 181, no. 2, pp. 281-292.e6, Apr. 2020, doi: 10.1016/j.cell.2020.02.058.

[17] K. S. Corbett et al., "Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates," N. Engl. J. Med., vol. 383, no. 16, pp. 1544–1555, Oct. 2020, doi: 10.1056/NEJMoa2024671.

[18] M. M. Lamers and B. L. Haagmans, "SARS-CoV-2 pathogenesis," Nat. Rev. Microbiol., vol. 20, no. 5, pp. 270–284, May 2022, doi: 10.1038/s41579-022-00713-0.

[19] K. Karikó et al., "Incorporation of Pseudouridine into mRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability," Mol. Ther., vol. 16, no. 11, pp. 1833–1840, Nov. 2008, doi: 10.1038/mt.2008.200.

[20] J. Devoldere, H. Dewitte, S. C. De Smedt, and K. Remaut, "Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger," Drug Discov. Today, vol. 21, no. 1, pp. 11–25, Jan. 2016, doi: 10.1016/j.drudis.2015.07.009.

[21] Y. Ingrasciotta, J. Sultana, U. Kirchmayer, and G. Trifirò, "Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy," BioDrugs, vol. 33, no. 4, pp. 345–352, Aug. 2019, doi: 10.1007/s40259-019-00365-2.

[22] A. Thess et al., "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals," Mol. Ther., vol. 23, no. 9, pp. 1456–1464, Sep. 2015, doi: 10.1038/mt.2015.103.

[23] M. Mockey, C. Gonçalves, F. P. Dupuy, F. M. Lemoine, C. Pichon, and P. Midoux, "mRNA transfection of dendritic cells: Synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level," Biochem. Biophys. Res. Commun., vol. 340, no. 4, pp. 1062–1068, Feb. 2006, doi: 10.1016/j.bbrc.2005.12.105.

[24] R. A. Wesselhoeft, P. S. Kowalski, F. C. Parker-Hale, Y. Huang, N. Bisaria, and D. G. Anderson, "RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo," Mol. Cell, vol. 74, no. 3, pp. 508-520.e4, May 2019, doi: 10.1016/j.molcel.2019.02.015.

[25] L. Schoenmaker et al., "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability," Int. J. Pharm., vol. 601, p. 120586, May 2021, doi: 10.1016/j.ijpharm.2021.120586.

[26] K. Bloom, F. Van Den Berg, and P. Arbuthnot, "Self-amplifying RNA vaccines for infectious diseases," Gene Ther., vol. 28, no. 3–4, pp. 117–129, Apr. 2021, doi: 10.1038/s41434-020-00204-y.

[27] M. Baiersdörfer et al., "A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA," Mol. Ther. - Nucleic Acids, vol. 15, pp. 26–35, Apr. 2019, doi: 10.1016/j.omtn.2019.02.018.

[28] N. Pardi et al., "Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes," J. Controlled Release, vol. 217, pp. 345–351, Nov. 2015, doi: 10.1016/j.jconrel.2015.08.007.

[29] S. M. Moghimi and Z. S. Farhangrazi, "Nanomedicine and the complement paradigm," Nanomedicine Nanotechnol. Biol. Med., vol. 9, no. 4, pp. 458–460, May 2013, doi: 10.1016/j.nano.2013.02.011.

[30] S. Ndeupen, Z. Qin, S. Jacobsen, A. Bouteau, H. Estanbouli, and B. Z. Igyártó, "The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory," iScience, vol. 24, no. 12, p. 103479, Dec. 2021, doi: 10.1016/j.isci.2021.103479.

[31] M. P. Lokugamage et al., "Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs," Nat. Biomed. Eng., vol. 5, no. 9, pp. 1059–1068, Oct. 2021, doi: 10.1038/s41551-021-00786-x.

[32] M. L. Guevara, F. Persano, and S. Persano, "Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy," Front. Chem., vol. 8, p. 589959, Oct. 2020, doi: 10.3389/fchem.2020.589959.

[33] L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, "Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3," Nature, vol. 413, no. 6857, pp. 732–738, Oct. 2001, doi: 10.1038/35099560.

[34] J. W. Park, P. N. P. Lagniton, Y. Liu, and R.-H. Xu, "mRNA vaccines for COVID-19: what, why and how," Int. J. Biol. Sci., vol. 17, no. 6, pp. 1446–1460, 2021, doi: 10.7150/ijbs.59233.

[35] J. R. Teijaro and D. L. Farber, "COVID-19 vaccines: modes of immune activation and future challenges," Nat. Rev. Immunol., vol. 21, no. 4, pp. 195–197, Apr. 2021, doi: 10.1038/s41577-021-00526-x.

[36] D. S. Khoury et al., "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection," Nat. Med., vol. 27, no. 7, pp. 1205–1211, Jul. 2021, doi: 10.1038/s41591-021-01377-8.

[37] A. E. Ringel et al., "Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity," Cell, vol. 183, no. 7, pp. 1848-1866.e26, Dec. 2020, doi: 10.1016/j.cell.2020.11.009.

[38] U. Sahin et al., "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses," Nature, vol. 586, no. 7830, pp. 594–599, Oct. 2020, doi: 10.1038/s41586-020-2814-7.

[39] R. R. Goel et al., "mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern," Science, vol. 374, no. 6572, p. abm0829, Dec. 2021, doi: 10.1126/science. abm0829.

[40] S. Chalkias et al., "A Bivalent Omicron-Containing Booster Vaccine against Covid-19," N. Engl. J. Med., vol. 387, no. 14, pp. 1279–1291, Oct. 2022, doi: 10.1056/NEJMoa2208343.

[41] M. Kanekiyo et al., "Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses," Nat. Immunol., vol. 20, no. 3, pp. 362–372, Mar. 2019, doi: 10.1038/s41590-018-0305-x.

[42] A. A. Cohen et al., "Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models," Science, vol. 377, no. 6606, p. eabq0839, Aug. 2022, doi: 10.1126/science. abq0839.

[43] J. Hadfield et al., "Nextstrain: real-time tracking of pathogen evolution," Bioinformatics, vol. 34, no. 23, pp. 4121–4123, Dec. 2018, doi: 10.1093/bioinformatics/bty407.

[44] A. B. Vogel et al., "BNT162b vaccines protect rhesus macaques from SARS-CoV-2," Nature, vol. 592, no. 7853, pp. 283–289, Apr. 2021, doi: 10.1038/s41586-021-03275-y.

[45] F. P. Polack et al., "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine," N. Engl. J. Med., vol. 383, no. 27, pp. 2603–2615, Dec. 2020, doi: 10.1056/NEJMoa2034577.

[46] L. R. Baden et al., "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine," N. Engl. J. Med., vol. 384, no. 5, pp. 403–416, Feb. 2021, doi: 10.1056/NEJMoa2035389.

https://doi.org/10.63954/67v24t98

[47] N. Dagan et al., "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting," N. Engl. J. Med., vol. 384, no. 15, pp. 1412–1423, Apr. 2021, doi: 10.1056/NEJMoa2101765.

[48] M. E. Oster et al., "Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US from December 2020 to August 2021," JAMA, vol. 327, no. 4, p. 331, Jan. 2022, doi: 10.1001/jama.2021.24110.

[49] P. Deepak et al., "Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study," Ann. Intern. Med., vol. 174, no. 11, pp. 1572–1585, Nov. 2021, doi: 10.7326/M21-1757.

[50] R. W. Frenck et al., "Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents," N. Engl. J. Med., vol. 385, no. 3, pp. 239–250, Jul. 2021, doi: 10.1056/NEJMoa2107456.

[51] R. L. Atmar et al., "Homologous and Heterologous Covid-19 Booster Vaccinations," N. Engl. J. Med., vol. 386, no. 11, pp. 1046–1057, Mar. 2022, doi: 10.1056/NEJMoa2116414.

[52] Z. Guan et al., "Mechanistic insights into the regulation of plant phosphate homeostasis by the rice SPX2 – PHR2 complex," Nat. Commun., vol. 13, no. 1, p. 1581, Mar. 2022, doi: 10.1038/s41467-022-29275-8.

[53] F. X. Heinz and K. Stiasny, "Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action," Npj Vaccines, vol. 6, no. 1, p. 104, Aug. 2021, doi: 10.1038/s41541-021-00369-6.

[54] L. Swadling et al., "Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2," Nature, vol. 601, no. 7891, pp. 110–117, Jan. 2022, doi: 10.1038/s41586-021-04186-8.

[55] J. S. Tregoning, K. E. Flight, S. L. Higham, Z. Wang, and B. F. Pierce, "Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape," Nat. Rev. Immunol., vol. 21, no. 10, pp. 626–636, Oct. 2021, doi: 10.1038/s41577-021-00592-1.

[56] D. Cromer et al., "Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis," Lancet Microbe, vol. 3, no. 1, pp. e52–e61, Jan. 2022, doi: 10.1016/S2666-5247(21)00267-6.

[57] J. S. Turner et al., "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses," Nature, vol. 596, no. 7870, pp. 109–113, Aug. 2021, doi: 10.1038/s41586-021-03738-2.

[58] A. Choi et al., "Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis," Nat. Med., vol. 27, no. 11, pp. 2025–2031, Nov. 2021, doi: 10.1038/s41591-021-01527-y.

[59] W. F. Garcia-Beltran et al., "mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant," Cell, vol. 185, no. 3, pp. 457-466.e4, Feb. 2022, doi: 10.1016/j.cell.2021.12.033.

[60] T. Zhao et al., "Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine," Npj Vaccines, vol. 5, no. 1, p. 47, Jun. 2020, doi: 10.1038/s41541-020-0194-5.

[61] L. C. Lambert and A. S. Fauci, "Influenza Vaccines for the Future," N. Engl. J. Med., vol. 363, no. 21, pp. 2036–2044, Nov. 2010, doi: 10.1056/NEJMra1002842.

[62] M. L. Guevara, F. Persano, and S. Persano, "Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy," Front. Chem., vol. 8, p. 589959, Oct. 2020, doi: 10.3389/fchem.2020.589959.

[63] Z. Kis et al., "Pandemic-response adenoviral vector and RNA vaccine manufacturing," Npj Vaccines, vol. 7, no. 1, p. 29, Mar. 2022, doi: 10.1038/s41541-022-00447-3.

[64] S. J. Ravi, A. I. Vecino-Ortiz, C. M. Potter, M. W. Merritt, and B. N. Patenaude, "Group-based trajectory models of integrated vaccine delivery and equity in low- and middle-income countries," Int. J. Equity Health, vol. 23, no. 1, p. 5, Jan. 2024, doi: 10.1186/s12939-023-02088-x.

[65] U. Sahin et al., "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer," Nature, vol. 547, no. 7662, pp. 222–226, Jul. 2017, doi: 10.1038/nature23003.

[66] D. Carroll et al., "The Global Virome Project," Science, vol. 359, no. 6378, pp. 872–874, Feb. 2018, doi: 10.1126/science. aap7463.

[67] M. M. Davis, C. M. Tato, and D. Furman, "Systems immunology: just getting started," Nat. Immunol., vol. 18, no. 7, pp. 725–732, Jul. 2017, doi: 10.1038/ni.3768.

[68] Z. Kis et al., "Pandemic-response adenoviral vector and RNA vaccine manufacturing," Npj Vaccines, vol. 7, no. 1, p. 29, Mar. 2022, doi: 10.1038/s41541-022-00447-3.

Declarations:

Authors' Contribution:

- All Authors contributed equally in conceptualizing, research, data collection and compilation of the manuscript
- The authors agree to take responsibility for every facet of the work, making sure that any concerns about its integrity or veracity are thoroughly examined and addressed

Correspondence:

Ali Abbas

microbiologist0603@gmail.com